AKR1C3 as a target in castrate resistant prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 137, Issue , 2013, Pages 136-149

  Adeniji, Adegoke O ^a   Chen, Mo ^a   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Androgens; Nonsteroidal anti inflammatory drugs; Prostaglandin F synthase; Prostate cancer; Type 5 17 hydroxysteroid dehydrogenase

Indexed keywords

ALDO KETO REDUCTASE 1 C3; ANDROGEN; ANDROSTANOLONE; BENZODIAZEPINE DERIVATIVE; CINNAMIC ACID; ENZALUTAMIDE; FLAVONOID; FLUFENAMIC ACID; INDOMETACIN; JASMONIC ACID; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CRYSTAL STRUCTURE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; IC 50; LIGAND BINDING; MALE PSEUDOHERMAPHRODITISM; PROSTATE; SOFT TISSUE METASTASIS; UPREGULATION;

EID: 84886588733     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.05.012     Document Type: Review

References (82)

1. SEER Cancer Statistics Review 1975-2009, based on November 2009 SEER data submission, posted to the SEER web site, 2010 2010 National Cancer Institute Bethesda, MD http://seer.cancer.gov/statfacts/html/prost.html
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010, CA Cancer Journal for Clinician 60 5 2010 277 300
3. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/ prostate-cancer-key-statistics
4. K.E. Knudsen, and H.I. Scher Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer Clinical Cancer Research 15 15 2009 4792 4798
5. K.E. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends in Endocrinology and Metabolism 21 5 2010 315 324
6. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, and C.C. Nelson Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Research 68 15 2008 6407 6415
7. G. Attard, A.H. Reid, T.A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, J. Clark, C.S. Cooper, S.B. Kaye, D. Dearnaley, G. Lee, and J.S. de Bono Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven Journal of Clinical Oncology 26 28 2008 4563 4571
8. G. Attard, A.H. Reid, R. A'Hern, C. Parker, N.B. Oommen, E. Folkerd, C. Messiou, L.R. Molife, G. Maier, E. Thompson, D. Olmos, R. Sinha, G. Lee, M. Dowsett, S.B. Kaye, D. Dearnaley, T. Kheoh, A. Molina, and J.S. de Bono Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer Journal of Clinical Oncology 27 23 2009 3742 3748
9. A.H. Reid, G. Attard, D.C. Danila, N.B. Oommen, D. Olmos, P.C. Fong, L.R. Molife, J. Hunt, C. Messiou, C. Parker, D. Dearnaley, J.F. Swennenhuis, L.W. Terstappen, G. Lee, T. Kheoh, A. Molina, C.J. Ryan, E. Small, H.I. Scher, and J.S. de Bono Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate Journal of Clinical Oncology 28 9 2010 1489 1495
10. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, and H.I. Scher Abiraterone and increased survival in metastatic prostate cancer New England Journal of Medicine 364 21 2011 1995 2005
11. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C.D. Chen, C.S. Higano, T.M. Beer, D.T. Hung, H.I. Scher, M.E. Jung, and C.L. Sawyers Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 5928 2009 787 790
12. M.E. Jung, S. Ouk, D. Yoo, C.L. Sawyers, C. Chen, C. Tran, and J. Wongvipat Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) Journal of Medicinal Chemistry 53 7 2010 2779 2796
13. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D. Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M. Hirmand, L. Seely, M.J. Morris, D.C. Danila, J. Humm, S. Larson, M. Fleisher, and C.L. Sawyers Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 9724 2010 1437 1446
14. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J.S. de Bono Increased survival with enzalutamide in prostate cancer after chemotherapy New England Journal of Medicine 367 13 2012 1187 1197
15. N.M. DeVore, and E.E. Scott Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 Nature 482 7383 2012 116 119
16. A. O'Donnell, I. Judson, M. Dowsett, F. Raynaud, D. Dearnaley, M. Mason, S. Harland, A. Robbins, G. Halbert, B. Nutley, and M. Jarman Hormonal impact of the 17α-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer British Journal of Cancer 90 12 2004 2317 2325 (Pubitemid 38961894)
17. J. Richards, A.C. Lim, C.W. Hay, A.E. Taylor, A. Wingate, K. Nowakowska, C. Pezaro, S. Carreira, J. Goodall, W. Arlt, I.J. McEwan, J.S. de Bono, and G. Attard Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Research 72 9 2012 2176 2182
18. http://investors.medivation.com/releasedetail.cfm?releaseid=703823
19. W.R. Foster, B.D. Car, H. Shi, P.C. Levesque, M.T. Obermeier, J. Gan, J.C. Arezzo, S.S. Powlin, J.E. Dinchuk, A. Balog, M.E. Salvati, R.M. Attar, and M.M. Gottardis Drug safety is a barrier to the discovery and development of new androgen receptor antagonists Prostate 71 5 2010 480 488
20. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochemical Journal 351 Pt 1 2000 67 77
21. H.K. Lin, J.M. Jez, B.P. Schlegel, D.M. Peehl, J.A. Pachter, and T.M. Penning Expression and characterization of recombinant type 2,3α- hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution Molecular Endocrinology 11 13 1997 1971 1984 (Pubitemid 27524880)
22. K.H. Chang, R. Li, M. Papari-Zareei, L. Watumull, Y.D. Zhao, R.J. Auchus, and N. Sharifi Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer Proceedings of the National Academy of Sciences of the United States of America 108 33 2011 13728 13733
23. R.J. Auchus The backdoor pathway to dihydrotestosterone Trends in Endocrinology and Metabolism 15 9 2004 432 438 (Pubitemid 39440726)
24. 2α stimulates the Raf/MEK1/mitogen-activated protein kinase signaling cascade in bovine luteal cells Endocrinology 139 9 1998 3876 3885 (Pubitemid 28512271)
25. 2 11-ketoreductase activity Journal of Biochemistry 124 5 1998 940 946 (Pubitemid 28544904)
26. T. Suzuki-Yamamoto, M. Nishizawa, M. Fukui, E. Okuda-Ashitaka, T. Nakajima, S. Ito, and K. Watanabe cDNA cloning, expression and characterization of human prostaglandin F synthase FEBS Letters 462 3 1999 335 340
27. M.J. Reginato, S.L. Krakow, S.T. Bailey, and M.A. Lazar Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma Journal of Biological Chemistry 273 4 1998 1855 1858 (Pubitemid 28069225)
28. 2α receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways Journal of Clinical Endocrinology and Metabolism 89 2 2004 986 993 (Pubitemid 38269922)
29. J.C. Desmond, J.C. Mountford, M.T. Drayson, E.A. Walker, M. Hewison, J.P. Ride, Q.T. Luong, R.E. Hayden, E.F. Vanin, and C.M. Bunce The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs Cancer Research 63 2 2003 505 512 (Pubitemid 36152514)
30. 2 is a ligand for the adipocyte determination factor PPARγ Cell 83 5 1995 803 812 (Pubitemid 3006324)
31. 2 inhibits androgen receptor signaling in prostate cancer cells Molecular Endocrinology 27 2 2012 212 223
32. N. Moghrabi, and S. Andersson 17β-hydroxysteroid dehydrogenases: physiological roles in health and disease Trends in Endocrinology and Metabolism 9 7 1998 265 270 (Pubitemid 28394973)
33. W.M. Geissler, D.L. Davis, L. Wu, K.D. Bradshaw, S. Patel, B.B. Mendonca, K.O. Elliston, J.D. Wilson, D.W. Russell, and S. Andersson Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3 Nature Genetics 7 1 1994 34 39
34. D.R. Bauman, S. Steckelbroeck, M.V. Williams, D.M. Peehl, and T.M. Penning Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α, 17β-diol to 5α-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease Molecular Endocrinology 20 2 2006 444 458 (Pubitemid 43152517)
35. J.L. Mohler, M.A. Titus, S. Bai, B.J. Kennerley, F.B. Lih, K.B. Tomer, and E.M. Wilson Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer Cancer Research 71 4 2011 1486 1496
36. J.L. Mohler, M.A. Titus, and E.M. Wilson Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone Clinical Cancer Research 17 18 2011 5844 5849
37. T.M. Penning, M.E. Burczynski, J.M. Jez, H.K. Lin, H. Ma, M. Moore, K. Ratnam, and N. Palackal Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Molecular and Cellular Endocrinology 171 1/2 2001 137 149 (Pubitemid 32098208)
38. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, and S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Research 66 5 2006 2815 2825
39. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Research 68 11 2008 4447 4454
40. J. Hofland, W.M. van Weerden, N.F. Dits, J. Steenbergen, G.J. van Leenders, G. Jenster, F.H. Schroder, and F.H. de Jong Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Research 70 3 2010 1256 1264
41. M.J. Pfeiffer, F.P. Smit, J.P. Sedelaar, and J.A. Schalken Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer Molecular Medicine 17 7/8 2011 657 664
42. C. Cai, S. Chen, P. Ng, G.J. Bubley, P.S. Nelson, E.A. Mostaghel, B. Marck, A.M. Matsumoto, N.I. Simon, H. Wang, and S.P. Balk Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Research 71 20 2011 6503 6513
43. T.M. Downs, D.W. Burton, F.L. Araiza, R.H. Hastings, and L.J. Deftos PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3 Cancer Letters 306 1 2011 52 59
44. M.G. Dozmorov, J.T. Azzarello, J.D. Wren, K.M. Fung, Q. Yang, J.S. Davis, R.E. Hurst, D.J. Culkin, T.M. Penning, and H.K. Lin Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression BMC Cancer 10 2010 672
45. P. Bydal, V. Luu-The, F. Labrie, and D. Poirier Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities European Journal of Medical Chemistry 44 2 2009 632 644
46. Y. Higaki, N. Usami, S. Shintani, S. Ishikura, O. El-Kabbani, and A. Hara Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone Chemico-Biological Interactions 143-144 2003 503 513 (Pubitemid 36253599)
47. N.J. Davies, R.E. Hayden, P.J. Simpson, J. Birtwistle, K. Mayer, J.P. Ride, and C.M. Bunce AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects Cancer Research 69 11 2009 4769 4775
48. P. Brozic, B. Golob, N. Gomboc, T.L. Rizner, and S. Gobec Cinnamic acids as new inhibitors of 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) Molecular and Cellular Endocrinology 248 1/2 2006 233 235
49. L. Skarydova, L. Zivna, G. Xiong, E. Maser, and V. Wsol AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids Chemico-Biological Interactions 178 1-3 2009 138 144
50. +-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins Proceedings of the National Academy of Sciences of the United States of America 80 14 1983 4504 4508 (Pubitemid 13077867)
51. D.R. Bauman, S.I. Rudnick, L.M. Szewczuk, Y. Jin, S. Gopishetty, and T.M. Penning Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes Molecular Pharmacology 67 1 2005 60 68 (Pubitemid 40069966)
52. S. Steckelbroeck, B. Oyesanmi, Y. Jin, S.H. Lee, H.J. Kloosterboer, and T.M. Penning Tibolone metabolism in human liver is catalyzed by 3α/3β-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily Journal of Pharmacology and Experimental Therapeutics 316 3 2006 1300 1309 (Pubitemid 43345306)
53. M.C. Byrns, S. Steckelbroeck, and T.M. Penning An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochemical Pharmacology 75 2 2008 484 493 (Pubitemid 350298472)
54. M.C. Byrns, Y. Jin, and T.M. Penning Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights Journal of Steroid Biochemistry and Molecular Biology 125 2011 95 104
55. M.E. Burczynski, R.G. Harvey, and T.M. Penning Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione Biochemistry 37 19 1998 6781 6790 (Pubitemid 28228113)
56. S. Steckelbroeck, Y. Jin, S. Gopishetty, B. Oyesanmi, and T.M. Penning Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action Journal of Biological Chemistry 279 11 2004 10784 10795 (Pubitemid 38379543)
57. V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, A. Maggi, P.G. Martini, B.S. Katzenellenbogen, L. Martini, M. Motta, and A. Poletti The androgen derivative 5α-androstane-3β, 17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype Cancer Research 65 12 2005 5445 5453 (Pubitemid 40827358)
58. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, J.D. Winkler, and T.M. Penning Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Bioorganic and Medicinal Chemistry Letters 21 5 2011 1464 1468
59. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, M. Chen, J.D. Winkler, and T.M. Penning Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships Journal of Medicinal Chemistry 55 5 2012 2311 2323
60. M. Sinreih, I. Sosic, N. Beranic, S. Turk, A.O. Adeniji, T.M. Penning, T.L. Rizner, and S. Gobec N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3 Bioorganic and Medicinal Chemistry Letters 22 18 2012 5948 5951
61. S.M. Jamieson, D.G. Brooke, D. Heinrich, G.J. Atwell, S. Silva, E.J. Hamilton, A.P. Turnbull, L.J. Rigoreau, E. Trivier, C. Soudy, S.S. Samlal, P.J. Owen, E. Schroeder, T. Raynham, J.U. Flanagan, and A.W. Denny 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly potent and selective inhibitors of the type 5 17β-hydroxysteroid dehydrogenase AKR1C3 Journal of Medicinal Chemistry 55 17 2012 7746 7758
62. D.J. Yee, V. Balsanek, and D. Sames New tools for molecular imaging of redox metabolism: development of a fluorogenic probe for 3α-hydroxysteroid dehydrogenases Journal of the American Chemical Society 126 8 2004 2282 2283 (Pubitemid 38295689)
63. C.P. Guise, M.R. Abbattista, R.S. Singleton, S.D. Holford, J. Connolly, G.U. Dachs, S.B. Fox, R. Pollock, J. Harvey, P. Guilford, F. Donate, W.R. Wilson, and A.V. Patterson The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 Cancer Research 70 4 2010 1573 1584
64. M. Chen, A.O. Adeniji, B.M. Twenter, J.D. Winkler, D.W. Christianson, and T.M. Penning Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer Bioorganic and Medicinal Chemistry Letters 22 10 2012 3492 3497
65. P. Brozic, S. Turk, A.O. Adeniji, J. Konc, D. Janezic, T.M. Penning, T. Lanisnik Rizner, and S. Gobec Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library Journal of Medicinal Chemistry 55 17 2012 7417 7424
66. D. Schuster, D. Kowalik, J. Kirchmair, C. Laggner, P. Markt, C. Aebischer-Gumy, F. Strohle, G. Moller, G. Wolber, T. Wilckens, T. Langer, A. Odermatt, and J. Adamski Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening Journal of Steroid Biochemistry and Molecular Biology 125 1/2 2011 148 161
67. S. Endo, T. Matsunaga, A. Kanamori, Y. Otsuji, H. Nagai, K. Sundaram, O. El-Kabbani, N. Toyooka, S. Ohta, and A. Hara Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis Journal of Natural Products 75 4 2012 716 721
68. A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, D.W. Christianson, L.J. Marnett, and T.M. Penning Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer Journal of Medicinal Chemistry 56 6 2013 2429 2446
69. C. Kandaswami, L.T. Lee, P.P. Lee, J.J. Hwang, F.C. Ke, Y.T. Huang, and M.T. Lee The antitumor activities of flavonoids In Vivo 19 5 2005 895 909
70. A. Krazeisen, R. Breitling, G. Moller, and J. Adamski Human 17β-hydroxysteroid dehydrogenase type 5 is inhibited by dietary flavonoids Advances in Experimental Medicine and Biology 505 2002 151 161 (Pubitemid 34526432)
71. M.L. Neuhouser Dietary flavonoids and cancer risk: evidence from human population studies Nutrition and Cancer 50 1 2004 1 7 (Pubitemid 39587599)
72. Y. Akao, H. Maruyama, K. Matsumoto, K. Ohguchi, K. Nishizawa, T. Sakamoto, Y. Araki, S. Mishima, and Y. Nozawa Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines Biological and Pharmaceutical Bulletin 26 7 2003 1057 1059 (Pubitemid 41685442)
73. S. Mishima, Y. Ono, Y. Araki, Y. Akao, and Y. Nozawa Two related cinnamic acid derivatives from Brazilian honey bee propolis, baccharin and drupanin, induce growth inhibition in allografted sarcoma S-180 in mice Biological & Pharmaceutical Bulletin 28 6 2005 1025 1030 (Pubitemid 40880309)
74. E. Efstathiou, M.A. Titus, D. Tsavachidou, A. Hoang, M. Karlou, S. Wen, P. Troncoso, R. Ashe, C.J. Berman, J. Mohler, and C. Logothetis MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report Journal of Clinical Oncology: ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2011 (abstr 4501)
75. C. Feau, L.A. Arnold, A. Kosinski, F. Zhu, M. Connelly, and R.K. Guy Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription ACS Chemical Biology 4 10 2009 834 843
76. V.J. Jackson, Y. Yosaatmadja, J.U. Flanagan, and C.J. Squire Structure of AKR1C3 with 3-phenoxybenzoic acid bound Acta Crystallographica Section F: Structural Biology and Crystallization Communications 68 Pt 4 2012 409 413
77. J.U. Flanagan, Y. Yosaatmadja, R.M. Teague, M.Z. Chai, A.P. Turnbull, and C.J. Squire Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3 PLoS ONE 7 8 2012 e43965
78. 2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin Cancer Research 64 5 2004 1802 1810 (Pubitemid 38428705)
79. M. Chen, A.O. Adeniji, B.M. Twenter, A.J. Liedtke, J.D. Winkler, L.J. Marnett, D.W. Christianson, and T.M. Penning Crystal structures of human 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) in complex with N-phenylanthranilic acid and indomethacin-based selective inhibitors Endocrine Reviews 33 03-MeetingAbstracts 2012 SAT-536
80. J. Komoto, T. Yamada, K. Watanabe, and F. Takusagawa Crystal structure of human prostaglandin F synthase (AKR1C3) Biochemistry 43 8 2004 2188 2198 (Pubitemid 38279964)
81. M.C. Byrns, and T.M. Penning Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs Chemico-Biological Interactions 178 1-3 2009 221 227
82. E. Estébanez-Perpiñá, L.A. Arnold, P. Nguyen, E.D. Rodrigues, E. Mar, R. Bateman, P. Pallai, K.M. Shokat, J.D. Baxter, R.K. Guy, P. Webb, and R.J. Fletterick A surface on the androgen receptor that allosterically regulates coactivator binding Proceedings of the National Academy of Sciences of the United States of America 104 41 2007 16074 16079 (Pubitemid 350099366)